Early in the 2014/15 influenza season, drifted influenza A(H3N2) viruses have predominated in Europe [1, 2] . In Finland, the season started earlier in the year than the previous season did (December 2014 as opposed to January 2014). We characterised a subset of circulating 2013/14 and 2014/15 influenza A(H3N2) viruses genetically to monitor changes in the circulating strains. On the basis of the genetic changes identified, representatives of these strains were selected for serological study. The strains recommended by the World Health Organization (WHO) for inclusion in the 2014/15 trivalent influenza vaccine (TIV) for the northern hemisphere [3] are the same as those in 2013/14 [4] 
Genetic characterisation of influenza A(H3N2) viruses in Finland in 2013/14 and 2014/15
As part of virological surveillance of influenza in Finland, a subset of influenza A(H3N2)-positive samples from sites in a sentinel influenza surveillance network and non-sentinel sites are selected throughout the season for genetic characterisation on the basis of their geographical origin and temporal distribution.
The sentinel network consists of healthcare centres collecting specimens from patients with influenza-like illness or acute respiratory infection and most also report clinical data. Healthcare centres of garrisons, also included in the network, only collect specimens. While intensive-care units are also part of the network, collecting specimens only, they are not considered as sentinel sites, as their participation is not agreed in advance (unlike that of healthcare centres). Other nonsentinel sites include clinical microbiology laboratories, for example.
Phylogenetic analysis of the haemagglutinin gene was performed as described previously [5] . Reference influenza A(H3N2) virus sequences for the phylogenetic tree were obtained from the EpiFlu database of the Global Initiative on Sharing Avian Influenza Data (GISAID) ( Table 1) .
During the 2013/14 season, a total of 27 influenza A(H3N2) viruses were analysed: 25 belonged to group 3C.3 and two to group 3C.2 ( Figure 1 , Table 1 ). Of the The assay was performed as previously described [6] using erythrocytes from turkeys for A(H1N1)pdm09 viruses and guinea pigs for A(H3N2) and influenza B viruses. A(H3N2) viruses were assayed in the presence of 20 nM oseltamivir carboxylate (Roche). For statistical analyses, serum specimens with HI titres < 10 were assigned a titre value of 5. We calculated the geometric mean titres (GMT) with 95% confidence intervals and presumable seroprotection rate (using the commonly accepted European Medicines Agency criteria [7] : HI titre ≥ 1:40) for each virus. For all virus strains tested, there was a significant (p < 0.01) increase in the GMTs of the antibody response three weeks after TIV vaccination (Table 2) . At six months, the GMTs decreased by 39.4-46.2%, 24.4-42.3% and 11.9-18.4% for influenza A(H1N1)pdm09, A(H3N2) and B viruses, respectively. The decrease was significant (p < 0.05 to p < 0.001) for both types influenza A viruses.
The baseline seroprotection rate for A(H1N1)pdm09 viruses was 57.0-58.2% (Figure 2 ). Three weeks after vaccination, the GMTs were higher for the recently circulating A/Finland/420/2014 strain than for the vaccine strain (p < 0.05). Post-vaccination seroprotection rates were 89.6% and 85. For drifted Finnish 3C.3a and 3C.2a viruses, baseline seroprotection rates were low (8.9% and 1.3%, respectively) and fivefold reductions in GMTs (for both) were detected three weeks after vaccination, compared with the vaccine strain. The reduction in GMTs for A/Finland/428/2014 (group 3C.3a) was in line with recently reported HI and neutralisation levels [8, 9] .
The baseline seroprotection rate for influenza B viruses was 26.6-27.8%. Three weeks after vaccination, very similar seroprotection rates were seen for vaccine strains B/Massachusetts/2/12 (61.0%) and B/Wisconsin/01/2010 (59.7%), which both represent the Yamagata-lineage viruses but belong to different clades.
Discussion
During the 2013/14 season, the relative prevalence of A(H1N1)pdm09, A(H3N2) and B influenza viruses varied from one European country to another [10] . In Finland, A(H1N1)pdm09 viruses predominated but A(H3N2) viruses were also detected. Most of the circulating A(H1N1)pdm09 and A(H3N2) viruses corresponded well with those included in the seasonal TIV vaccine for that season. Viruses from patients requiring intensive care were not proven genetically different from other circulating viruses [11] .
Representatives of influenza A(H3N2) groups 3C.2 and 3C.3 were found in Europe in the 2013/14 season and since February 2014, two new genetic subgroups, 3C.2a and 3C.3a, emerged in these clusters [8, 10] . Both of these genetic subgroups contain viruses that show antigenic drift from the vaccine virus [1] . In Control and Prevention has issued a health advisory notice regarding the circulation of drifted influenza A(H3N2) viruses in the US [12] . Early estimates of the current seasonal influenza vaccine effectiveness from the US and Canada suggest low effectiveness against circulating A(H3N2) viruses [13, 14] .
New antigenic A(H3N2) clusters appear on average every 3.3 years [15] . Seven amino acid locations have been shown to be responsible for the major antigenic changes in A(H3N2) viruses [16] . Subgroup 3C.2a and 3C.3a viruses carry specific amino acid substitutions that drifted from the corresponding main groups. Both subgroups have a substitution at position 159, which has shown to be one of seven positions responsible for the major antigenic changes between 1968 and 2003 A(H3N2) viruses [16] .
In our analysis of antibody response, GMTs against the circulating A/Finland/428/2014 virus (a group 3C.3a A(H3N2) virus) were found to be significantly lower [9] and previous serological studies [8] . The pre-vaccination seroprotection rate of the HCWs we tested for this virus variant was only less than 10%. Even at three weeks after vaccination, the cross-protection rate was only less than 30% and decreased to less than 10% within 6 months.
The GMTs were found to be significantly lower against the currently circulating subgroup 3C. We acknowledge at least a few limitations in our serological analysis. First, the number of HCWs included in the study was limited. Secondly, the HCWs we tested did not represent all age groups: thus the results do not necessarily apply to children or elderly individuals. Antibody responses to influenza A(H1N1)pdm09 vaccination are age dependent [18] and low vaccine effectiveness against A(H3N2) has been reported among elderly persons [19] . For influenza B viruses, the overall impact of lineage-level mismatch between vaccine and circulating strains has been shown to be considerable, especially among children and adolescents [20] . Thirdly, HCWs are often vaccinated more regularly than others (in Finland, influenza vaccination is recommended for all HCWs who come in contact with patients) and they are also at higher risk of contracting influenza virus. The impact of repeated vaccination on vaccine effectiveness against influenza is still under investigation and discussion [21, 22] .
In conclusion, our serological data suggest that although the 2013/14 and 2014/15 TIV would protect against A(H1N1)pdm09 viruses, the protection against influenza A(H3N2) 3C.2a and 3C.3a virus variants would be suboptimal. The current epidemic situation in the northern hemisphere underlines the need to change the A(H3N2) component of the 2015/16 vaccine to a virus that represents one of the drifted groups. With minimal pre-existing immunity and a limited crossprotective effect from the TIV, the population in the northern hemisphere may be more susceptible to the new influenza A(H3N2) virus variants during the current 2014/15 season. However, influenza vaccination is strongly encouraged for HCWs, as well as for persons in risk groups, to reduce influenza disease burden and the spread of the epidemics.
